Clinical Trials Browser

Phase 1/2 × Lung Neoplasms × Cetuximab × Clear all

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT07223047 2026-04-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07286149 2026-04-09

MK-3475-01F

Phase 1/2 Recruiting

Lung Neoplasms

NCT02845856 2019-09-12

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00408499 2017-05-08

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Phase 1/2 Completed

64 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00716456 2015-04-30

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Phase 1/2 Completed

21 enrolled 8 charts

Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms